EP1196435A1 - Recombinant adenovirus - Google Patents
Recombinant adenovirusInfo
- Publication number
- EP1196435A1 EP1196435A1 EP00946680A EP00946680A EP1196435A1 EP 1196435 A1 EP1196435 A1 EP 1196435A1 EP 00946680 A EP00946680 A EP 00946680A EP 00946680 A EP00946680 A EP 00946680A EP 1196435 A1 EP1196435 A1 EP 1196435A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- adenovirus
- fiber
- seq
- adenovirus according
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 56
- 239000000835 fiber Substances 0.000 claims abstract description 115
- 239000003446 ligand Substances 0.000 claims abstract description 33
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 230000010415 tropism Effects 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 238000001727 in vivo Methods 0.000 claims abstract description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 15
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 14
- 229940116977 epidermal growth factor Drugs 0.000 claims description 14
- 229940024606 amino acid Drugs 0.000 claims description 12
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 3
- 210000000172 cytosol Anatomy 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 101710128836 Large T antigen Proteins 0.000 claims description 2
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 claims description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000002095 exotoxin Substances 0.000 claims description 2
- 231100000776 exotoxin Toxicity 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101000632467 Homo sapiens Pulmonary surfactant-associated protein D Proteins 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 102400001368 Epidermal growth factor Human genes 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 11
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000030648 nucleus localization Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241001135569 Human adenovirus 5 Species 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 101710145505 Fiber protein Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 102220080600 rs797046116 Human genes 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Definitions
- the present invention relates to new recombinant - adenovirus with changed tropism. More particularly the recombinant adenovirus has been constructed by removing the native knob structure and replacing it with a new cell binding ligand and an external trimerisation motif. The invention also relates to the new adenovirus for treatment of human diseases. Also included is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome.
- Clinical gene therapy was introduced in 1989. The aim at that time was to correct a gene defect in the immune system through the in vitro introduction of a healthy gene into the defect cells of the patient and transfusion of the treated cells back to the patient. Since that time, the possible indications for gene therapy have increased dramatically.
- gene therapy to treat e.g. diseases of the blood vessels, cancer, inflammatory diseases and infectious diseases such as HIV can be envisaged.
- gene therapy is not a useful method in human medicine.
- gene therapy demands the packaging of the genes to be delivered into gene-carriers, or vectors, which can be injected into patients and which will target the genes only to the intended cells.
- vectors have so far not been available .
- Adenoviruses are DNA viruses without an envelope, shaped as regular icosahedrons with a diameter of 60-85 nm. Cell-binding takes place through fiber proteins, anchored to the virion at the corners of the icosahedron. The fiber protein is not necessary for assembly and release of intact virions. Assembly of virions take place in the nucleus of infected cells.
- the fiber protein which is a homotrimer of a fiber polypeptide, contains three functionally different parts: an N-terminal tail anchoring the fiber non-covalently to the penton base in the virion and which furthermore contains the nuclear-localization signal; an approximate 15 amino acid fiber shaft motif which is repeated six times in Ad3 and 22 times in Ad2 and Ad5 (Chrobozek J, Ruigrok RWH and Cusack S: Adenovirus Fiber, Current
- Each shaft repeat has two three-amino acid regions which form ⁇ - sheets and two amino acid regions which constitute the turns of the native extended fiber shaft.
- the crystal structure of the trimerised, cell-binding domain has been determined and shows a unique topology different from other anti-parallel ⁇ -sandwiches (Di Xia, Henry LJ,
- Gerard RD and Deisenhofer J Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution, Structure 2: 1259-1270, 1994.) . Binding of the fiber to the penton base of the virion can take place also in a cell-free system, i.e. the fiber can bind to fiberless virions (Boudin M-L and Boulanger P: Assembly of Adenovirus Penton Base and Fiber, Virology, 116: 589-604, 1982).
- the FLAG tetra-amino acid motif By introducing the FLAG tetra-amino acid motif into the Ad penton, it has .been shown possible to target Ad to cells normally not infected by Ad. This was done by targeting with bi-specific antibodies where one specificity was directed against the FLAG peptide and the other against the new target cell (Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM and Kovesdi I: Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies. J. Virol . , 70 : 6831 - 6838 , 1996. ) .
- Another object of the invention is the recombinant adenovirus for treatment of human diseases.
- a further object of the invention is a method for rescuing of recombinant adenovirus fibers into the adnovirus genome.
- the objects of the invention are obtained by the recombinant adenovirus and the method for rescuing the virus fibers as claimed in the claims.
- a recombinant adenovirus with changed tropism is characterized in that the native pentone fibre, which comprises a fibre tail, a fibre shaft and a fibre knob including a trimerisation motif, has been changed in that the native knob containing the cell binding structure and the native trimerisation motif has been removed and a new cellbinding ligand and an external trimerisation motif have been introduced into the virus fiber.
- the structural modification has been performed by DNA technology at the gene level or by chemical or immunological means at the virus level .
- adenovirus as identified above, is used for the treatment of human diseases, either in vivo or by in vitro methods.
- a further aspect of the invention is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome comprising the following steps:
- Sequence listing containing an Xhol site d) ligation of recombinant fiber between Ndel and Xhol of construct under c) above; e) re-introduction of construct under d) above into the 9 kb fragment cut with Nhel using homologous recombination in E. coli; f) isolation of the recombinant 9 kb fragment under e) and re-creation of the adenovirus genome by joining 9 kb fragment to the 27 kb fragment from the beginning of the genome to the Spel site by Cosmid cloning.
- Fig. 1 Summary of modifications to native fiber carried out in the invention.
- Fig. 2 Recombinant adenovirus fibers.
- Fig. 3 Method for rescuing of recombinant fiber genes into the Ad genome .
- Fig. 4a Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures.
- Fig. 4b Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures .
- re-targeting of Ad is achieved through the introduction of a new cell-binding ligand into the fiber (Fig. 1) .
- a new cell-binding ligand e.g. a monoclonal antibody or a fragment thereof whether as a single chain fragment or Fab, a T cell receptor or a fragment thereof, an integrin binding peptide such as RGD or a growth factor such as Epidermal Growth Factor.
- Ligands which so far have been applied include Epidermal Growth Factor (EGF) , the amino acid motif RGD, a single chain fragment of a cloned T-cell receptor (scTCR) reactive with MAGE-1 peptides associated with HIA-A1 (vd Bruggen P, Traversaari C, Chomez P, Lurquin D, De Plaen E, vd Eynde B, Knuth A and Boon T: A Gene encoding an EGF-derived neurotrophic factor (vd Bruggen P, Traversaari C, Chomez P, Lurquin D, De Plaen E, vd Eynde B, Knuth A and Boon T: A Gene encoding an
- Ad vectors can be made replication competent or incompetent for permissive cells.
- replication competent Ad has the potential advantage that it can replicate and spread within the tumor (Miller R and Curiel DT: Towards the use of replicative adenoviral vectors for cancer gene therapy, Gene Therapy 3: 557- 559) . This may theoretically result in an increase of the chosen effector mechanism over that obtainable with replication incompetent vectors.
- infectious virus may contribute to an anti tumor effect by cytopathogenic effects in infected cells as well as by evoking an anti viral immune response which may harm infected cells.
- the aim has been to develop a universal method for the construction of functional Ad fibers with changed binding-specificity to make possible the construction of re-targeted Ad.
- the adenovirus fiber peptide carries several biological functions which are necessary to retain in order to produce active virus particles.
- the following fiber features are deemed to be of key importance in the construction of functional recombinant fiber peptides:
- recombinant fibers are constructed and evaluated in vitro after cell-free expression in a coupled transcription/translation system. Analysis by SDS-PAGE and autoradiography is performed to reveal the presence of an open reading frame and give information on the size of the translated product.
- next stage recombinant fibers are cloned into Baculovirus and expressed in insect cells allowing for functional studies of the fibers. Such studies include ability to form trimers as evaluated by immunostaining with monoclonal antibody 2A6.36 which has been shown to react only with trimerised fibers (Shin Hong J and Engler JA: The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal, Virology 185: 758-767,
- Recombinant fibers are constructed using, methodology based on PCR (Clackson T, G ⁇ ssow D and Jones PT: General application of PCR to gene cloning and manipulation, in PCR, A Practical Approach, Eds McPherson MJ, Quirke P and Taylor GR, IRL Press, Oxford, p 187, 1992), e.g. PCR- ligation-PCR (Alvaro Ali S, Steinkasserer A: PCR- ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations, BioTechniqrues 18: 746-750, 1995) and splicing by overlap extension (SOE) (Horton RM and
- Pease LR Recombination and mutagenesis of DNA sequences using PCR, in McPherson MJ (ed) , Directed Mutagenesis, IRL Press 1991, p 217.) . Cloning is performed according to standard methods. Recombinant fibers are sequenced using Perkin Elmer ABI Prism and are expressed in mammalian cells and in insect cells and stained with monoclonal antibodies specific for fiber tail, trimeric fiber and the new cell-binding ligand. The following parameters are evaluated after immunostaining :
- Fiber peptides are made where the knob is replaced with an external trimerisation motif which is introduced after the TLWT motif which ends the shaft portion of the fiber.
- the purpose behind the introduction of an external trimerisation motif is two-fold: a) to remove the knob containing the native trimerisation signal but also the cell-binding part of the fiber, and b) simultaneously to supply the necessary trimerisation signal.
- trimerisation motifs are synthesized, cloned and sequenced in the project.
- a new cellbinding ligand is introduced into the fiber in addition to the external trimerisation amino acid motif.
- the fiber in addition contains sequences which increase the survival of the fiber in the cytosol of infected cells, thereby enhancing transportation into the nucleus and virus assembly.
- sequences are e.g. sequences that are present in the wild type knob or in SEQ ID NO: 10 - 12.
- Type A where the trimerisation motif is fused to the fiber gene downstream of the fiber shaft after the TL T motif which constitutes the four first amino acids of the fiber knob or downstream of the second turn (Turn b) of any shaft repeat, the remaining shaft repeats having been removed.
- the new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
- Type B similar to type A but with a linker motif introduced immediately upstream of the trimerisation signal .
- Type C where the trimerisation motif is introduced after the first shaft repeat and in turn followed the shaft repeats 17 through 21.
- the new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
- Type D where the cellbinding ligand is introduced between the restriction sites Nhel and Hpal in the fiber shaft, with an amino acid linker being added both upstream and downstream of the ligand.
- Type D/ ⁇ where the cellbinding ligand is introduced between the restriction sites Nhel and Hpal in the fiber shaft, with an amino acid linker being added both upstream and downstream of the ligand.
- Type D This is a variant of Type D where the fiber shaft downstream of the cellbinding ligand in Type D was removed.
- Type D and (D/ ⁇ ) are constructed with the normal knob and with the knob being replaced with an external trimerisation signal as in Types A and B.
- Type E which are similar to Type A but with part of the knob being retained immediately upstream of the external trimerisation motif.
- Recombinant fibers are cloned into Baculovirus and expressed in Sf9 cells and/or cloned into the vector pSecTag and expressed in COS cells as secreted proteins. Expression is monitored by immunostaining with monoclonal antibodies 4D2.5 (anti Ad5 fiber) and 2A6.36 (anti trimerised Ad5 fiber) . Expression and trimerisation is obvious in all recombinant fibers irrespective of length and trimerisation motif.
- 4D2 antibody against fiber a-EGF: antibody against epidermal growth factor a-Id: anti idiotypic antibody specific for G250 a-Ig: antibody against mouse immunoglobulin
- C ⁇ Constant domain from ⁇ chain of T cell receptor against MAGEl/HLA Al . SEQ ID NO: 11.
- CH2 immunoglobulin heavy chain constant domain 2
- EGF epidermal growth factor
- G250 monoclonal antibody specific for renal carcinoma
- H heavy chain variable sequence from G250 (SEQ ID NO:
- IgG3 amino acid linker derived from hinge region of human IgG3 , SEQ ID NO: 7
- RGD The amino acid sequence arginine-glycine-aspartic acid
- V ⁇ Variable domain from ⁇ chain of T ceil receptor against MAGEl/HLA Al .
- SEQ ID NO: 12 Example 2
- Nuclear localization is assessed by immunostaining of fibers in Sf9 cells 24 hours after infection with the relevant Baculovirus clone. Some results are shown in Table 2 below. It is clear from these experiments that some recombinant fibers show a grossly impaired nuclear localization in Sf9 cells despite the presence of the nuclear addressing signal in the fiber tail.
- Recombinant and native fibers have also been expressed in COS cells, targeted for expression in the cytosol after cloning into the vector pcDNA 3.1.
- the fibers would be detected in the nucleus, due to the presence of the native nuclear localization signal in the fiber tail.
- nuclear localization has so far only been detected in the wild type fiber and in fibers with single-chain T-cell receptors, i.e. the fibers which have produced the most efficient virus (se below) .
- NLS nuclear localization signal
- SEQ ID NO: 9 the amino acid sequence SEQ ID NO: 9 (Fisher-Fantuzzi L and Vesco C: Cell -Dependent Efficiency of Reiterated Nuclear Signals in a Mutant Simian Virus 40 Oncoprotein Targeted to the Nucleus. Mol Cell Biol , 8:5495-5503, 1988).
- the external NLS sequence is added immediately up-stream of the RGD motif. It is found that the presence of the external NLS dramatically improved the nuclear localization in the cases where it has been investigated. In fact, as mentioned above the fiber constructs lacking the external NLS were undetectable in the transfected cells (Table 3) .
- the wild type fiber in the Ad genome is exchanged for recombinant fibers by the following method (see Fig 3) .
- the plasmid pTG3602 (Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A and Mehtali M: Efficient generation of Recombinant Adenovirus Vectors by Homologous Recombination i Escherichia Coli, J Virol , 70: 4805-4810, 1996) containing the entire Ad5 genome as a Pacl-Pacl fragment is used as starting material.
- Pacl and containing the wild type fiber gene is cloned separately in pBluescript. From this fragment an approximate 3kb fragment between Sacl and Kpnl is further subcloned.
- a deletion of the native fiber gene with the exception of the N-terminal nucleotides upstream of the Ndel site of the fiber, between the Ndel site and the Muni site, which begins at base 38 after the stop codon of the fiber, is created in the 3kb fragment.
- the deleted sequence is replaced with SEQ ID NO: 13 which restores the Ndel and Muni sites and the wild type genome sequence between the fiber stop codon and the Muni site.
- SEQ ID NO: 13 contains an Xhol site allowing for ligation of recombinant fibers into the fiber-deleted 3kb fragment (the 3 kb fiber shuttle) between Ndel and Xhol.
- the 3 kb fiber shuttle with recombinant fiber is re- introduced into the 9 kb fragment cut with Nhel using homologous recombination in E.coli (see ref. in previous passage) .
- the resulting recombinant 9 kb fragment is finally excised from the vector with Spel and Pacl and joined to the isolated 27 kb fragment by Cosmid cloning.
- Cosmid clones are also restricted with Hind III and the presence of restriction fragments of the expected size verified on gels.
- Recombinant Ad genomes are isolated after restriction with Pac 1 and used to transfect suitable cells. The occurrence of plaques is determined by microscopic inspection of the transfected cell cultures.
- Supernatants are harvested from primarily transfected cultures and used to infect secondary cultures. The occurrence of cytopathogenic effects and plaques are monitored by microscopy.
- the present invention describes methods whereby knobless, trimerisation-competent fibers with new cellbinding ligands can been created and rescued into virus and have identified locations within the fiber-shaft which tolerates inserts of foreign ligands.
- the importance of intracellular trafficking of recombinant fibers has also been identified.
- Recombinant virus made using the invented technology should be highly useful in human medicine. Virtually unlimited opportunities for targeted gene-therapy may be developed by the combination of the technology described here and the identification of cell- binding ligands by phage-display.
- Ad made re-targeted by the present invention
- tumor diseases the following options exist:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Recombinant adenovirus with changed tropism. In the adenovirus the native pentone fibre, comprising a fibre tail, a fibre shaft and a fibre knob including a trimerisation motif, has been changed in that the native knob containing the cell binding structure and the native trimerisation motif has been removed and a new cellbinding ligand and an external trimerisation motif have been introduced into the virus fiber. Further, the invention relates to the recombinant adenovirus for the treatment of human diseases, either in vivo or by in vitro methods and also to a method for rescuing of recombinant adenovirus fibers into the adenovirus genome.
Description
RECOMBINANT ADENOVIRUS
Field of the invention
The present invention relates to new recombinant - adenovirus with changed tropism. More particularly the recombinant adenovirus has been constructed by removing the native knob structure and replacing it with a new cell binding ligand and an external trimerisation motif. The invention also relates to the new adenovirus for treatment of human diseases. Also included is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome.
Background of the invention.
Clinical gene therapy was introduced in 1989. The aim at that time was to correct a gene defect in the immune system through the in vitro introduction of a healthy gene into the defect cells of the patient and transfusion of the treated cells back to the patient. Since that time, the possible indications for gene therapy have increased dramatically. Today, ten years after its introduction, the use of gene therapy to treat e.g. diseases of the blood vessels, cancer, inflammatory diseases and infectious diseases such as HIV can be envisaged.
At present, however, gene therapy is not a useful method in human medicine. One main reason is that gene therapy demands the packaging of the genes to be delivered into gene-carriers, or vectors, which can be injected into
patients and which will target the genes only to the intended cells. Such vectors have so far not been available .
Adenoviruses (Ad) are DNA viruses without an envelope, shaped as regular icosahedrons with a diameter of 60-85 nm. Cell-binding takes place through fiber proteins, anchored to the virion at the corners of the icosahedron. The fiber protein is not necessary for assembly and release of intact virions. Assembly of virions take place in the nucleus of infected cells.
The fiber protein, which is a homotrimer of a fiber polypeptide, contains three functionally different parts: an N-terminal tail anchoring the fiber non-covalently to the penton base in the virion and which furthermore contains the nuclear-localization signal; an approximate 15 amino acid fiber shaft motif which is repeated six times in Ad3 and 22 times in Ad2 and Ad5 (Chrobozek J, Ruigrok RWH and Cusack S: Adenovirus Fiber, Current
Topics in Microbiology and Immunology, 1995, p 163-200); and a C-terminal globular domain, the knob, which contains the ligand which binds to the cellular Ad- receptor (See review in in the previous ref.) . Each shaft repeat has two three-amino acid regions which form β- sheets and two amino acid regions which constitute the turns of the native extended fiber shaft. The crystal structure of the trimerised, cell-binding domain has been determined and shows a unique topology different from other anti-parallel β-sandwiches (Di Xia, Henry LJ,
Gerard RD and Deisenhofer J: Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution, Structure 2: 1259-1270,
1994.) . Binding of the fiber to the penton base of the virion can take place also in a cell-free system, i.e. the fiber can bind to fiberless virions (Boudin M-L and Boulanger P: Assembly of Adenovirus Penton Base and Fiber, Virology, 116: 589-604, 1982).
It seems possible that the fiber can tolerate structural modifications as long as the ability to bind to the penton base and to be transported to the nucleus is retained. Some attempts at modifying the Ad fiber in order to change the binding properties of the virus have been made. A short peptide ligand has been added C- terminally of the knob (Michael SI, Hoy JS, Curie DT and Engles JT : Addition of a short peptide ligand to the adenvorirus fiber protein. Gene Therapy 2 : 660-8, 1995. ) and an octapeptide has been introduced into one of the knob "loops". By introducing the FLAG tetra-amino acid motif into the Ad penton, it has .been shown possible to target Ad to cells normally not infected by Ad. This was done by targeting with bi-specific antibodies where one specificity was directed against the FLAG peptide and the other against the new target cell (Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM and Kovesdi I: Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies. J. Virol . , 70 : 6831 - 6838 , 1996. ) . It would therefore seem possible to target Ad to a broad range of human cells which would be very useful for the purpose of human gene therapy. For these reasons and for the reason that Ad have been used extensively for gene therapeutic applications (Trapnell BC and Gorziglia: Gene therapy using adenoviral vectors, Current Opinion in Biotechnology, 5: 617-625, 1994.) a method has now been
developed to create recombinant re-targeted Ad-virus which can be useful for human gene therapy.
Accordingly it is an object of the present invention to provide a recombinant adenovirus with changed tropism.
Another object of the invention is the recombinant adenovirus for treatment of human diseases.
A further object of the invention is a method for rescuing of recombinant adenovirus fibers into the adnovirus genome.
Summary of the invention
The objects of the invention are obtained by the recombinant adenovirus and the method for rescuing the virus fibers as claimed in the claims.
According to the invention there is provided a recombinant adenovirus with changed tropism. The adenovirus is characterized in that the native pentone fibre, which comprises a fibre tail, a fibre shaft and a fibre knob including a trimerisation motif, has been changed in that the native knob containing the cell binding structure and the native trimerisation motif has been removed and a new cellbinding ligand and an external trimerisation motif have been introduced into the virus fiber.
The structural modification has been performed by DNA technology at the gene level or by chemical or immunological means at the virus level .
According to another aspect of the invention adenovirus, as identified above, is used for the treatment of human diseases, either in vivo or by in vitro methods.
A further aspect of the invention is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome comprising the following steps:
a) subcloning of a 9kb fragment (from Spel to end of genome) , b) further subcloning of a 3kb fragment between Sacl and Kpnl, c) deletion of the fibergene between Ndel and Muni and replacing the missing sequence with SEQ ID NO: 13 in the
Sequence listing containing an Xhol site; d) ligation of recombinant fiber between Ndel and Xhol of construct under c) above; e) re-introduction of construct under d) above into the 9 kb fragment cut with Nhel using homologous recombination in E. coli; f) isolation of the recombinant 9 kb fragment under e) and re-creation of the adenovirus genome by joining 9 kb fragment to the 27 kb fragment from the beginning of the genome to the Spel site by Cosmid cloning.
Detailed description of the invention
Figure legends
Fig. 1: Summary of modifications to native fiber carried out in the invention.
Fig. 2: Recombinant adenovirus fibers.
Fig. 3: Method for rescuing of recombinant fiber genes into the Ad genome .
Fig. 4a: Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures.
Fig. 4b: Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures .
In the present invention re-targeting of Ad is achieved through the introduction of a new cell-binding ligand into the fiber (Fig. 1) . Any cell binding peptide can be used, e.g. a monoclonal antibody or a fragment thereof whether as a single chain fragment or Fab, a T cell receptor or a fragment thereof, an integrin binding peptide such as RGD or a growth factor such as Epidermal Growth Factor. Ligands which so far have been applied include Epidermal Growth Factor (EGF) , the amino acid motif RGD, a single chain fragment of a cloned T-cell receptor (scTCR) reactive with MAGE-1 peptides associated with HIA-A1 (vd Bruggen P, Traversaari C, Chomez P, Lurquin D, De Plaen E, vd Eynde B, Knuth A and Boon T: A Gene encoding an
Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma, Science 13 December 1991, 1643-1647.), a single chain fragment (scFv) of the monoclonal antibody G250, which with high selectivity has been shown to react with a protein antigen, on human renal carcinoma cells
(Oosterwijk E, Ruiter DJ, Hoedemaeker PhJ, et al : Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Jnt J Cancer 38: 489-94, 1986.) . G250 has been extensively evaluated and has been applied in clinical trials (see the previous ref.) .
Ad vectors can be made replication competent or incompetent for permissive cells. For tumor therapy, replication competent Ad has the potential advantage that it can replicate and spread within the tumor (Miller R and Curiel DT: Towards the use of replicative adenoviral
vectors for cancer gene therapy, Gene Therapy 3: 557- 559) . This may theoretically result in an increase of the chosen effector mechanism over that obtainable with replication incompetent vectors. Furthermore, infectious virus may contribute to an anti tumor effect by cytopathogenic effects in infected cells as well as by evoking an anti viral immune response which may harm infected cells.
Construction, expression and evaluation of recombinant fibers
The aim has been to develop a universal method for the construction of functional Ad fibers with changed binding-specificity to make possible the construction of re-targeted Ad.
The adenovirus fiber peptide carries several biological functions which are necessary to retain in order to produce active virus particles. The following fiber features are deemed to be of key importance in the construction of functional recombinant fiber peptides:
• The ability to form parallel homotrimers . This function is carried by the N-terminal amino acid sequence of the wild type fiber knob and is necessary for the fiber to be able to bind to penton base and to form the functional cell binding knob.
• The ability to bind to penton base to form penton capsomeres. This function is carried by the wild type fiber tail. • The ability to express a cell-binding ligand allowing for attachment to target cells. This function is carried by the wild type fiber knob.
• Since adenovirus is assembled in the nucleus of infected cells, the ability to be transported into the nucleus of infected cells is vital to virus formation. The nuclear localization signal is mainly, but perhaps not exclusively, carried by the wild type fiber tail.
In the first stage recombinant fibers are constructed and evaluated in vitro after cell-free expression in a coupled transcription/translation system. Analysis by SDS-PAGE and autoradiography is performed to reveal the presence of an open reading frame and give information on the size of the translated product. In the next stage recombinant fibers are cloned into Baculovirus and expressed in insect cells allowing for functional studies of the fibers. Such studies include ability to form trimers as evaluated by immunostaining with monoclonal antibody 2A6.36 which has been shown to react only with trimerised fibers (Shin Hong J and Engler JA: The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal, Virology 185: 758-767,
1991) , expression of functional ligand as evidenced by ability to bind to cells expressing the corresponding receptor and ability to bind to penton-base either in solution or on virions.
Recombinant fibers are constructed using, methodology based on PCR (Clackson T, Gύssow D and Jones PT: General application of PCR to gene cloning and manipulation, in PCR, A Practical Approach, Eds McPherson MJ, Quirke P and Taylor GR, IRL Press, Oxford, p 187, 1992), e.g. PCR- ligation-PCR (Alvaro Ali S, Steinkasserer A: PCR- ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations, BioTechniqrues 18: 746-750, 1995)
and splicing by overlap extension (SOE) (Horton RM and
Pease LR: Recombination and mutagenesis of DNA sequences using PCR, in McPherson MJ (ed) , Directed Mutagenesis, IRL Press 1991, p 217.) . Cloning is performed according to standard methods. Recombinant fibers are sequenced using Perkin Elmer ABI Prism and are expressed in mammalian cells and in insect cells and stained with monoclonal antibodies specific for fiber tail, trimeric fiber and the new cell-binding ligand. The following parameters are evaluated after immunostaining :
• trimerisation
• nuclear transportation
• expression of the new cell-binding ligand.
Finally, recombinant fibers are rescued into the Ad genome by a newly invented procedure described below and recombinant virus particles are produced. '
The invention will be further illustrated with the following non-limiting examples:
Exampl e 1 :
Fiber peptides are made where the knob is replaced with an external trimerisation motif which is introduced after the TLWT motif which ends the shaft portion of the fiber. The purpose behind the introduction of an external trimerisation motif is two-fold: a) to remove the knob containing the native trimerisation signal but also the cell-binding part of the fiber, and b) simultaneously to supply the necessary trimerisation signal. Two different amino acid motifs have been used, i.e. the 36 amino acid "Neck Region Peptide" = NRP (SEQ ID NO: 1 in Sequence
listing) from human "Lung Surfactant Protein D" (. Hoppe
H-J, Barlow PN and Reid KBM: A parallel three stranded helicalbundle at the nucleation site of collagen triple- helix formation. FEBS Letters 344: 191-195 (1994).) and a 31 aa "Zipper" motif where the leucine residues on positions 1 and 4 have been replaced with isoleucine residues = pll (SEQ ID NO: 2 in Sequence listing) (Harbury PB, Tao Zhang, Kim PS and Alber T: A Switch Between Two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants. Sci ence 262: 1401-1407, 1993.) .
The DNA sequences for these trimerisation motifs are synthesized, cloned and sequenced in the project.
To replace the cellbinding function of the knob a new cellbinding ligand is introduced into the fiber in addition to the external trimerisation amino acid motif.
To augment the efficiency of nuclear transportation of recombinant fibers an external nuclear localisation sequence is added to the fiber in some cases.
In further embodiments the fiber in addition contains sequences which increase the survival of the fiber in the cytosol of infected cells, thereby enhancing transportation into the nucleus and virus assembly. Such sequences are e.g. sequences that are present in the wild type knob or in SEQ ID NO: 10 - 12.
The following types of fibers are constructed using the methods mentioned above (see Fig 2) . The sequence of the
wild type fiber is shown in the sequence listing as SEQ
ID NO 14.
Type A where the trimerisation motif is fused to the fiber gene downstream of the fiber shaft after the TL T motif which constitutes the four first amino acids of the fiber knob or downstream of the second turn (Turn b) of any shaft repeat, the remaining shaft repeats having been removed. The new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
Type B similar to type A but with a linker motif introduced immediately upstream of the trimerisation signal .
Type C where the trimerisation motif is introduced after the first shaft repeat and in turn followed the shaft repeats 17 through 21. The new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
Type D where the cellbinding ligand is introduced between the restriction sites Nhel and Hpal in the fiber shaft, with an amino acid linker being added both upstream and downstream of the ligand.
Type D/Δ
This is a variant of Type D where the fiber shaft downstream of the cellbinding ligand in Type D was removed. Type D and (D/Δ) are constructed with the normal knob and with the knob being replaced with an external trimerisation signal as in Types A and B.
Type E which are similar to Type A but with part of the knob being retained immediately upstream of the external trimerisation motif.
The following amino acid motifs are used as linkers in the above fiber constructs:
• SEQ ID NO 3 , derived from Psedomonas exotoxin
• SEQ ID NO 4, derived from tissue prothrombin activator
• SEQ ID NO 5, derived from the hinge region of mouse immunoglobulin • SEQ ID NO: 6, derived from Staphylococcal protein A
• SEQ ID NO: 7, derived from the hinge region of human IgG3
• SEQ ID NO: 8, derived from shaft repeat no 17 of human Ad5
Recombinant fibers are cloned into Baculovirus and expressed in Sf9 cells and/or cloned into the vector pSecTag and expressed in COS cells as secreted proteins. Expression is monitored by immunostaining with monoclonal antibodies 4D2.5 (anti Ad5 fiber) and 2A6.36 (anti trimerised Ad5 fiber) . Expression and trimerisation is
obvious in all recombinant fibers irrespective of length and trimerisation motif.
The various fibers which have been constructed and shown to be able to form trimers and express the new cell binding ligand are shown in Table 1. The results show that the invented technology is capable of generating trimerising fibers which express a new cellbinding ligand. It should therefore be possible to make functional virus with such fibers.
Table I. Results from immunostaining of different recombinant fibers
Detecting antibody
Fiber 4D2 2A6 a-EGF a-Ig a-Id Type A
Al RGD
Al EGF + + Al G250 HK + + + + Al G250 KH + + + + Al G250 KHJCH2 + + + + Al VαLVβCβ + + A7 RGD + +
A7 EGF + +
A7 G250 HK + + + +
A7 G250 KH + + + +
A7 G250 KHJCH2 + + + + A7 VαLVβCβ + +
A7 IgG3 EGF +
A7 (Gly4Ser)4 G250VKVH +
A22 EGF + +
A22 RGD + +
Type B
B (Gly4Ser) 4 RGD + +
Type C
C IgG3 EGF + +
C (Gly4Ser)4-
G250VKVH + +
Type D
N/D EGF + + +
N/D G250 HKCKγ + +
F2/D EGF + + +
F3/D EGF + + +
Type D/Δ
F2 D/Δ G250 HKCK + + +
F2 D/Δ G250 HKCKγ + +
F2 D/Δ EGF + + +
F3 D/Δ EGF + + +
Abbreviations used in Table 1:
2A6 : antibody against trimerized fiber
4D2 : antibody against fiber a-EGF: antibody against epidermal growth factor a-Id: anti idiotypic antibody specific for G250 a-Ig: antibody against mouse immunoglobulin
Cβ : Constant domain from β chain of T cell receptor against MAGEl/HLA Al . SEQ ID NO: 11.
CH2 : immunoglobulin heavy chain constant domain 2 EGF: epidermal growth factor
G250: monoclonal antibody specific for renal carcinoma
H: heavy chain variable sequence from G250 (SEQ ID NO:
15)
IgG3: amino acid linker derived from hinge region of human IgG3 , SEQ ID NO: 7
J: immunoglobulin joining chain sequence
K: light chain variable sequence from monclonal antibody G250 (SEQ ID NO: 16)
RGD: The amino acid sequence arginine-glycine-aspartic acid
Vet: Variable domain from α chain of T cell receptor against MAGEl/HLA Al . SEQ ID NO: 10
Vβ: Variable domain from β chain of T ceil receptor against MAGEl/HLA Al . SEQ ID NO: 12
Example 2
Nuclear localization of recombinant fibers (Tables 2 and 3)
Nuclear localization is assessed by immunostaining of fibers in Sf9 cells 24 hours after infection with the relevant Baculovirus clone. Some results are shown in Table 2 below. It is clear from these experiments that some recombinant fibers show a grossly impaired nuclear localization in Sf9 cells despite the presence of the nuclear addressing signal in the fiber tail.
Recombinant and native fibers have also been expressed in COS cells, targeted for expression in the cytosol after cloning into the vector pcDNA 3.1. In this case it was expected that the fibers would be detected in the nucleus, due to the presence of the native nuclear localization signal in the fiber tail. However, nuclear localization has so far only been detected in the wild type fiber and in fibers with single-chain T-cell
receptors, i.e. the fibers which have produced the most efficient virus (se below) .
Since nuclear localization of fibers are crucial to virus assembly, an attempt is made to improve the efficiency of nuclear addressing by adding an external nuclear localization signal (NLS) , in this case the SV40 large T- antigen NLS having the amino acid sequence SEQ ID NO: 9 (Fisher-Fantuzzi L and Vesco C: Cell -Dependent Efficiency of Reiterated Nuclear Signals in a Mutant Simian Virus 40 Oncoprotein Targeted to the Nucleus. Mol Cell Biol , 8:5495-5503, 1988). The external NLS sequence is added immediately up-stream of the RGD motif. It is found that the presence of the external NLS dramatically improved the nuclear localization in the cases where it has been investigated. In fact, as mentioned above the fiber constructs lacking the external NLS were undetectable in the transfected cells (Table 3) .
The evidence given above support the hypothesis that recombinant fibers are poorly transported into the nucleus despite the presence of the intact tail region
(see also below) and that this may possibly be corrected by the incorporation of an external NLS in the fiber construct .
Example 3 :
METHOD FOR RESCUING OF RECOMBINANT FIBERS INTO VIRIONS
The wild type fiber in the Ad genome is exchanged for recombinant fibers by the following method (see Fig 3) .
The plasmid pTG3602 (Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A and Mehtali M: Efficient generation of Recombinant Adenovirus Vectors by Homologous Recombination i Escherichia Coli, J Virol , 70: 4805-4810, 1996) containing the entire Ad5 genome as a Pacl-Pacl fragment is used as starting material. The approximate 9kb fragment of the genome between Spel and
Pacl and containing the wild type fiber gene is cloned separately in pBluescript. From this fragment an approximate 3kb fragment between Sacl and Kpnl is further subcloned. A deletion of the native fiber gene with the exception of the N-terminal nucleotides upstream of the Ndel site of the fiber, between the Ndel site and the Muni site, which begins at base 38 after the stop codon of the fiber, is created in the 3kb fragment. The deleted sequence is replaced with SEQ ID NO: 13 which restores the Ndel and Muni sites and the wild type genome sequence between the fiber stop codon and the Muni site. In addition the added sequence, SEQ ID NO: 13, contains an Xhol site allowing for ligation of recombinant fibers
into the fiber-deleted 3kb fragment (the 3 kb fiber shuttle) between Ndel and Xhol.
The 3 kb fiber shuttle with recombinant fiber is re- introduced into the 9 kb fragment cut with Nhel using homologous recombination in E.coli (see ref. in previous passage) . The resulting recombinant 9 kb fragment is finally excised from the vector with Spel and Pacl and joined to the isolated 27 kb fragment by Cosmid cloning.
The presence of an insert of the expected properties is verified in all cosmid clones by PCR. Cosmid clones are also restricted with Hind III and the presence of restriction fragments of the expected size verified on gels.
Recombinant Ad genomes are isolated after restriction with Pac 1 and used to transfect suitable cells. The occurrence of plaques is determined by microscopic inspection of the transfected cell cultures.
Supernatants are harvested from primarily transfected cultures and used to infect secondary cultures. The occurrence of cytopathogenic effects and plaques are monitored by microscopy.
The particular fiber constructs that have been successfully rescued into virus are shown in figure 4a and 4b.
Conclusion:
For gene therapy to be useful for treatment of human diseases there is a need for injectable vectors with ability to target specific cells or a specific tissue (Miller N and Vile R: Targeted vectors for gene therapy. FASEB J, 9: 190-199, 1995).
The present invention describes methods whereby knobless, trimerisation-competent fibers with new cellbinding ligands can been created and rescued into virus and have identified locations within the fiber-shaft which tolerates inserts of foreign ligands. The importance of intracellular trafficking of recombinant fibers has also been identified. Recombinant virus made using the invented technology should be highly useful in human medicine. Virtually unlimited opportunities for targeted gene-therapy may be developed by the combination of the technology described here and the identification of cell- binding ligands by phage-display.
So far trimerisation-competent fibers with a human scTCR have been and rescued into functional virus. Since single chain antibodies are large and highly complex peptides it seems highly likely that also other scAbs and cell- binding ligands, e.g. peptides identified from peptide libraries by means of phage-display, could be incorporated into Ad-fibers and rescued into virus using the same technology.
There are many ways in which Ad, made re-targeted by the present invention, may be applied to human gene therapy.
In the case of tumor diseases, the following options exist :
I. Use of vectors to introduce transgenes into tumors, such as
• anti onco genes " * -
• "suicide" genes
• genes for immune modulatory substances or tumor antigens • genes for anti angiogenetic factors
II. Use of infectious virus. This has the added value over the use of non replicating vectors that virus can spread from cell to cell within a tumor, thereby multiplying the initial hit on the tumor. Tumor cell destruction may occur not only by the cell -destroying mechanism engineered into the vector but also by the cell destruction which is associated with the virus infection per se and by the attack of the body' s immune response on the virus infected cells. This principle has already been tested in man through the direct intra-tumoral injection of an adenovirus which has been made gene manipulated to replicate only in p53 mutant tumor cells. The experience from these limited trials on large "head-and-neck" tumors are partially encouraging with a complete regress of 2/11 treated tumors which are otherwise resistant to any form of known treatment .
Claims
1. Recombinant adenovirus with changed tropism, characterized in that the native pentone fibre, comprising a fibre tail, a fibre shaft and a fibre knob including a trimerisation motif, has been changed in that the native knob containing the cell binding structure and the native trimerisation motif has been removed and a new cellbinding ligand and an external trimerisation motif have been introduced into the virus fiber.
2. Adenovirus according to claim 1, chracterized in that said structural modification has been performed by DNA technology at the gene level or by chemical or immunological means at the virus level .
3. Adenovirus according to claim 1 which is either replication competent or replication in-competent.
4. Adenovirus according to claim 1, characterized in that the new cellbinding ligand has been introduced into the fiber shaft.
5. Adenovirus according to claim 1, characterized in that the new cell binding ligand has been introduced downstream of the fiber shaft repeats.
6. Adenovirus according to claim 4 characterized in that the new cellbinding ligand has been introduced between the restriction sites Nhel and Hpal in the fiber shaft.
7. Adenovirus according to claim 4, characterized in that amino acid linkers have been introduced upstream and downstream of the cellbinding ligand.
8. Adenovirus according to claim 4, characterized in that the shaft repeats downstream of the restriction site Hpal have been removed.
9. Adenovirus according to claim 1, characterized in that an amino acid linker motif has been added between the fiber shaft and the trimerisation motif and/or between the trimerisation motif and the cellbinding ligand as a linker.
10. Adenovirus according to claim 9, characterized in that the amino acid linker motif is any of the following: SEQ ID NO: 3, derived from Psedomonas exotoxin; SEQ ID NO: 4, derived from tissue prothrombin activator; SEQ ID NO: 5, derived from the hinge region of mouse immunoglobulin; SEQ ID NO: 6, derived from Staphylococcal protein A; SEQ ID NO: 7, derived from the hinge region of human IgG3 ; SEQ ID NO: 8, derived from shaft repeat 17 of human Ad5.
11. Adenovirus according to any of the claims 1 - 10, characterized in that the new cellbinding ligand is any cellbinding peptide.
12. Adenovirus according to claim 11, characterized in that the cell binding ligand is a monoclonal antibody or a fragment thereof whether as a single chain fragment or Fab, a T cell receptor or a fragment thereof, an integrin binding peptide such as RGD or a growth factor such as Epidermal Growth Factor.
13. Adenovirus according to claim 12, containing any of the sequences SEQ ID NO: 10 - 12.
14. Adenovirus according to claim 12, characterized in that the single chain fragment is a single chain fragment of the monoclonal antibody G250 with heavy chain variable region with SEQ ID NO: 15 and light chain variable region with SEQ ID NO: 16.
15. Adenovirus according to claim 1 characterized in that the external trimerisation motif is an α-helical coiled coil motif , or any other peptide capable of rendering functionally trimerised fibers.
16. Adenovirus according to claim 15, characterized in that the external trimerisation motif is the neck region peptide of human lung surfactant protein D, SEQ ID NO : 1 or a 31 aa "Zipper" motif where the leucine residues on positions 1 and 4 have been replaced with isoleucine residues, SEQ ID NO: 2.
17. Adenovirus according to any of the preceding claims characterized in that an external nuclear localisation signal (NLS) has been introduced in the fiber.
18. Adenovirus according to claim 17, characterized in that the NLS is the SV40 large-T antigen NLS.
19. Adenovirus according to any of the preceding claims characterized in that the fiber in addition contains sequences which increase the survival of the fiber in the cytosol of infected cells, thereby enhancing transportation into the nucleus and virus assembly.
20. Adenovirus according to claim 19, characterized in that the sequences are present in the wild type knob.
21. Adenovirus according to claim 20, characterized in that the sequences are present in SEQ ID NO: 10 - 12.
22. Adenovirus according to claims 1 - 21 for the treatment of human diseases, either in vivo or by in vitro methods.
23. A method of producing a recombinant adenovirus with changed tropism, comprising:
I . rescuing recombinant adenovirus fibres into the adenovirus genome by the following steps: a) subcloning of a 9kb fragment (from Spel to end of genome) , b) further subcloning of a 3kb fragment between Sacl and Kpnl , c) deletion of the native fibergene coding for the native penton fibre between Ndel and Muni and replacing the missing sequence with the sequence SEQ ID NO: 13 containing an Xhol site; d) ligation of recombinant fiber gene coding for between Ndel and Xhol of construct under c) above; e) re-introduction of construct under d) above into the 9 kb fragment cut with Nhel using homologous recombination in E. coli; f) isolation of the recombinant 9 kb fragment under e) and re-creation of the adenovirus genome by joining 9 kb fragment to the 27 kb fragment from the beginning of the genome to the Spel site by Cosmid cloning; and
II. transfecting a cell with the adenovirus obtained in step f) to enable said cell to express the recombinant adenovirus .
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9902601A SE9902601D0 (en) | 1999-07-06 | 1999-07-06 | Recombinant adenovirus |
| SE9902601 | 1999-07-06 | ||
| US14363299P | 1999-07-14 | 1999-07-14 | |
| US143632P | 1999-07-14 | ||
| PCT/SE2000/001390 WO2001002431A1 (en) | 1999-07-06 | 2000-06-30 | Recombinant adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1196435A1 true EP1196435A1 (en) | 2002-04-17 |
Family
ID=26663617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00946680A Withdrawn EP1196435A1 (en) | 1999-07-06 | 2000-06-30 | Recombinant adenovirus |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1196435A1 (en) |
| JP (1) | JP2003531568A (en) |
| KR (1) | KR20020092886A (en) |
| CN (1) | CN1359391A (en) |
| AU (1) | AU763733B2 (en) |
| CA (1) | CA2378324A1 (en) |
| WO (1) | WO2001002431A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081607A2 (en) * | 2000-04-26 | 2001-11-01 | Crucell Holland B.V. | Adenovirus vectors with knobless fibers, and their uses |
| AU6368901A (en) | 2000-05-31 | 2001-12-11 | Univ Saskatchewan | Modified bovine adenovirus having altered tropism |
| GB0017720D0 (en) * | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| EP1358318B8 (en) * | 2001-02-07 | 2006-11-15 | Wilex AG | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20040077081A1 (en) | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| EP1524995B1 (en) | 2002-07-01 | 2011-12-21 | Wilex AG | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| EP1842548A4 (en) * | 2004-11-30 | 2010-01-06 | Kiim Pharm Lab Inc | Anti-hiv drug, polypeptide constituting the same, gene encoding the polypeptide and method of producing the anti-hiv drug |
| WO2007094653A1 (en) * | 2006-02-13 | 2007-08-23 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles. |
| EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
| CN102775500A (en) * | 2012-08-03 | 2012-11-14 | 郑骏年 | Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| CN104634978A (en) * | 2013-11-13 | 2015-05-20 | 长春百克生物科技股份公司 | Method for performing typing testing on adenovirus neutralizing antibody, and kit for performing typing testing on adenovirus neutralizing antibody |
| CN107683289B (en) * | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2 binding agents and their use in cancer therapy |
| JP7015551B2 (en) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Exogenous gene expression in therapeutic adenovirus to minimize its impact on viral dynamics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN107602672B (en) * | 2017-08-30 | 2021-06-18 | 广州医科大学附属第一医院 | Recombinantly expressed adenovirus ciliary protein peptide, adenovirus subunit vaccine and preparation method thereof |
| CN107365365B (en) * | 2017-08-30 | 2021-01-01 | 广州医科大学附属第一医院 | Recombinant expression adenovirus cilia protein peptide, adenovirus subunit vaccine and preparation method thereof |
| BR112020019942A2 (en) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | oncolytic adenovirus compositions with enhanced replication properties |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| IL124654A0 (en) * | 1995-11-28 | 1998-12-06 | Genvec Inc | Vectors and method for gene transfer to cells |
| US5871727A (en) * | 1995-12-08 | 1999-02-16 | Uab Research Foundation | Targeted adenovirus vectors |
| AU751542B2 (en) * | 1998-02-17 | 2002-08-22 | Uab Research Foundation, The | Modified adenovirus containing a fiber replacement protein |
-
2000
- 2000-06-30 JP JP2001508218A patent/JP2003531568A/en active Pending
- 2000-06-30 CA CA002378324A patent/CA2378324A1/en not_active Abandoned
- 2000-06-30 WO PCT/SE2000/001390 patent/WO2001002431A1/en not_active Ceased
- 2000-06-30 KR KR1020027000132A patent/KR20020092886A/en not_active Withdrawn
- 2000-06-30 EP EP00946680A patent/EP1196435A1/en not_active Withdrawn
- 2000-06-30 AU AU60401/00A patent/AU763733B2/en not_active Ceased
- 2000-06-30 CN CN00809885A patent/CN1359391A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0102431A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003531568A (en) | 2003-10-28 |
| CA2378324A1 (en) | 2001-01-11 |
| WO2001002431A1 (en) | 2001-01-11 |
| AU6040100A (en) | 2001-01-22 |
| AU763733B2 (en) | 2003-07-31 |
| CN1359391A (en) | 2002-07-17 |
| KR20020092886A (en) | 2002-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU763733B2 (en) | Recombinant adenovirus | |
| ES2246533T3 (en) | MODIFIED ADENOVIRICAL FIBER AND ADENOVIRUS DIANAS. | |
| CA2213343C (en) | Chimeric adenoviral fiber protein and methods of using same | |
| Krasnykh et al. | Genetic targeting of adenoviral vectors | |
| AU734515B2 (en) | A short-shafted adenoviral fiber and its use | |
| US20080286292A1 (en) | Molecular vaccine linking intercellular spreading protein to an antigen | |
| JP2003508057A (en) | Modified adenovirus fibers and uses | |
| JP4683682B2 (en) | Gene delivery vector imparted tissue tropism to smooth muscle cells and / or endothelial cells | |
| AU2004238979B2 (en) | Broadening adenovirus tropism | |
| Ambriović-Ristov et al. | Shortening adenovirus type 5 fiber shaft decreases the efficiency of postbinding steps in CAR-expressing and nonexpressing cells | |
| CA2256696C (en) | Modified small rna viruses | |
| US20050003548A1 (en) | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof | |
| WO2001092299A9 (en) | Adenovirus particles with mutagenized fiber proteins | |
| JP2007514429A (en) | Adapter for linking substances that can be linked to the cell surface | |
| US20020137213A1 (en) | Adenovirus particles with mutagenized fiber proteins | |
| JP2003514577A (en) | Modified adenovirus fibers and uses | |
| AU723006B2 (en) | Modified small RNA viruses | |
| WO2004011489A2 (en) | Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells | |
| Medina-Kauwe | A Novel Gene Delivery System Targeted to fireast Cancer Cells | |
| Van Kessel | Molecular and functional characterization of the IIIA protein of porcine adenovirus type 3 | |
| Mikheeva et al. | Genetic Targeting of an Adenovirus Vector | |
| Van Kessel | Characterization of the IIIa protein of porcine adenovirus type 3 | |
| Mahasreshti et al. | Identification of Sites in Adenovirus Hexon | |
| Miller | Modification of the viral and cellular requirements for adenovirus entry into cells | |
| Curiel | Conditionally Replicative Adenovirus for Prostate Cancer Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020204 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20030716 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRCL |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20050505 |